Akebia Therapeutics, Inc.
Biopharmaceuticals for renal disease, including small-molecule therapeutics in clinical development and marketed medicines
New patent ·
- Sector
- Biotech
- Headquarters
- CINCINNATI, OH
- Founded
- 2007
- Latest Form D
- $12M, Apr 2011
- Total capital
- $12M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $12M
- 1 Form D · last Apr 2011
- 187 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 26
- 14 pending · first 2018
- Rank in peer group#53 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$12M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#53 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Robert ShalwitzResearcherExecutive OfficerLinked by 1 patent
- Anupam DalalDirectorNamed in SEC Form D filings
- Campbell MurrayDirectorNamed in SEC Form D filings
- Ian HowesExecutive OfficerNamed in SEC Form D filings
- John RiceDirectorNamed in SEC Form D filings
- Joseph GardnerExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Kevin PetersExecutive OfficerNamed in SEC Form D filings
- Paul WeissDirectorNamed in SEC Form D filings
What it has protected
USPTO · 26 granted of 40- New patentPhd Inhibitor Compounds, Compositions, And UseUSPTOUS 12,753,161
- PendingSolid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, And Uses ThereofUSPTOApplication 19319408
- GrantedPhd Inhibitor Compounds, Compositions, And Their UseUSPTOUS 12,703,691
Show all 40 patent records
- Phd Inhibitor Compounds, Compositions, And UseOct 6, 2026 · US 12,753,161Granted
- Solid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, And Uses ThereofSep 10, 2026 · Application 19319408Pending
- Phd Inhibitor Compounds, Compositions, And Their UseAug 11, 2026 · US 12,703,691Granted
- Therapeutic Methods Using VadadustatAug 4, 2026 · US 12,697,330Granted
- Process For Preparing [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC Acids, Esters And AmidesJul 7, 2026 · US 12,673,919Granted
- Treatment Of Viral Infections, Of Organ Injury, And Of Related Conditions Using A Hif Prolyl Hydroxylase Inhibitor Or A Hif-alpha StabilizerMay 19, 2026 · US 12,629,357Granted
- Method For Producing Nitrogen-containing Heteroarylcarboxamide Acetic Acid DerivativeApr 28, 2026 · US 12,612,367Granted
- Compositions And Methods For Treating AnemiaMar 10, 2026 · US 12,569,474Granted
- Prolyl Hydroxylase Inhibitors And Methods Of UseNov 25, 2025 · US 12,478,615Granted
- Methods For Treating Viral Infections, Organ Injury, And Related ConditionsNov 20, 2025 · Application 18991047Pending
- Solid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, And Uses ThereofSep 23, 2025 · US 12,419,877Granted
- Process For Preparing 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC AcidJul 31, 2025 · Application 19071033Pending
- Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic AcidApr 8, 2025 · US 12,269,802Granted
- Selective PHD1 Inhibitor Compounds, Compositions, And Methods Of UseOct 10, 2024 · Application 18742052Pending
- Compositions and Methods for Treating AnemiaOct 3, 2024 · Application 18500471Pending
- Picolinamide Compounds As Selective PHD1 Inhibitors, Compositions, And Methods Of UseOct 3, 2024 · Application 18742035Pending
- METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATORSep 12, 2024 · Application 18542100Pending
- Modulation Of Drug-drug Interactions Of VadadustatMay 9, 2024 · Application 18279680Pending
- Prolyl Hydroxylase Inhibitors And Methods Of UseJan 30, 2024 · US 11,883,386Granted
- Compositions And Methods For Treating AnemiaJan 2, 2024 · US 11,857,543Granted
- Compositions and Methods for Treating AnemiaDec 19, 2023 · US 11,844,756Granted
- Phd Inhibitor Compounds, Compositions, And Methods Of UseSep 21, 2023 · Application 18041490Pending
- Manufacturing Process For 3,5-DICHLOROPICOLINONITRILE For Synthesis Of VadadustatSep 14, 2023 · Application 18012012Pending
- Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic AcidAug 1, 2023 · US 11,713,298Granted
- Phd Inhibitor Compounds, Compositions, And UseJul 20, 2023 · Application 17906650Pending
- Phd Inhibitor Compounds, Compositions, And Their UseJul 6, 2023 · Application 17906653Pending
- Solid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, And Uses ThereofJul 4, 2023 · US 11,690,836Granted
- Phd Inhibitor Compounds, Compositions, And UseMay 25, 2023 · Application 17906652Pending
- Methods For Treating Viral Infections, Organ Injury, And Related ConditionsMay 11, 2023 · Application 17974000Pending
- Solid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC AcidDec 13, 2022 · US 11,524,939Granted
- Prolyl Hydroxylase Inhibitors And Methods Of UseAug 30, 2022 · US 11,426,393Granted
- Compositions and Methods for Treating AnemiaMay 10, 2022 · US 11,324,734Granted
- Process For Preparing [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC Acids, Esters And AmidesMar 8, 2022 · US 11,267,785Granted
- Solid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, And Uses ThereofJul 20, 2021 · US 11,065,237Granted
- Process For Preparing [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC Acids, Esters And AmidesAug 11, 2020 · US 10,738,010Granted
- Prolyl Hydroxylase Inhibitors And Methods Of UseAug 4, 2020 · US 10,729,681Granted
- Solid Forms Of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, And Uses ThereofMar 24, 2020 · US 10,596,158Granted
- Prolyl Hydroxylase Inhibitors And Methods Of UseJun 18, 2019 · US RE47,437Granted
- Process For Preparing [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC Acids, Esters And AmidesApr 2, 2019 · US 10,246,416Granted
- Solid Forms Of 2-(5-(3-FLUOROPHENYL)-3-HYDROXYPICOLINAMIDO)ACETIC Acid, Compositions, And Uses ThereofDec 11, 2018 · US 10,150,734Granted
Related companies, and why
- HDL THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Encellin, Inc.Similar federal contract value in Biotech · null in contracts
- MACROGENICS INCSimilar federal contract value in Biotech · null in contracts
- Silo Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- FENNEC PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- Syrna Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .